Vitrolife AB (publ) Company Profile
The fourth of the total of twelve patients included in the USA study for STEEN Solution™, and which enables sales approval in the important USA market, has now received a transplant. The first transplantation was carried out in September and four transplantations have thus now been carried out at four centres. A fifth centre, Duke University, has been included in the study, and it is anticipated that they will be able to start within approximately one month there.
News Articles
Vitrolife AB (publ): Information regarding the distribution of Xvivo Perfusion AB
Regulatory News: Vitrolife (STO:VITR): In accordance with the resolution adopted by the Extraordinary General Meeting of shareholders held on September 24, Vitrolife's transplantation business, wh...
Vitrolife AB (Publ): Vitrolife's Share Capital and Number of Shares on November 30, 2012
Regulatory News: As per November 30, 2012, the total number of shares in Vitrolife AB (publ) (STO:VITR)Â amounts to 19,830,936, of which Vitrolife itself holds 0 shares. The share capital amounts t...
Notice of Annual General Meeting of Vitrolife AB (publ)
Regulatory News: The Annual General Meeting of Vitrolife AB (publ) (STO:VITR) will take place on Monday April 29, 2013, at 5 p.m. in the company's premises at Gustaf Werners gata 2 in Gothenburg. ...
Vitrolife AB (publ): Annual report 2012
Regulatory News: Today Vitrolife (STO:VITR) is publishing the Annual Report for 2012 in Swedish. The Annual Report is attached to this press release and will also be available on www.vitrolife.com...
Report from the Extraordinary General Meeting of Vitrolife AB (Publ) Held on September 24, 2012
Regulatory News: Vitrolife AB (STO:VITR): 1. The meeting adopted a resolution to distribute shares in the subsidiary Xvivo Perfusion AB to company shareholders, whereby one (1) existing share in V...
Carsten Browall proposed as new Chairman of Vitrolife AB (publ)
Regulatory News: The Election Committee of Vitrolife AB (publ) has proposed Carsten Browall as the new Chairman of the Board. Carsten Browall is today a member of the company's Board and he has ma...
Vitrolife AB (Publ): Private Placement Regarding Cryo Management Fully Subscribed
Regulatory News: The Extraordinary General Meeting of Vitrolife (STO:VITR) held on September 24 adopted a resolution regarding a private placement of EUR 1.352.315 in order to partly finance the a...
Report from Annual General Meeting of Vitrolife AB (publ)
Regulatory News: At Vitrolife's (STO:VITR) Annual General Meeting yesterday, April 29, the following, amongst other things, was decided: The Board's proposed dividend of SEK 0.60 per share for the...
Drugs and Medications
Kepivance [Swedish Orphan Biovitrum AB (publ)]
These highlights do not include all the information needed to use Kepivance safely and effectively. See full prescribing information for Kepivance.Kepivance® (palifermin) For injection, for intraveno...
Kineret [Swedish Orphan Biovitrum AB (publ)]
These highlights do not include all the information needed to use Kineret safely and effectively. See full prescribing information for Kineret. Kineret® (anakinra) For injection, for subcutaneous use...
PubMed Articles
OBJECTIVE: To compare the development of abnormal pronuclear zygotes after intracytoplasmic sperm injection (ICSI) and analyze their genetic polymorphism. METHODS: Four hundred and ninety three abnorm...
INTRODUCTION: Longitudinal data are increasingly available to health researchers; these present challenges not encountered in cross-sectional data, not the least of which is the presence of time-varyi...
Clinical Trials
None
Companies
The fourth of the total of twelve patients included in the USA study for STEEN Solution™, and which enables sales approval in the important USA market, has now received a tra...
Karolinska Development AB (publ), and BioChromix AB
Karolinska Development manages one of the largest portfolios of life science companies in Europe.
The purpose of the GAD65-based diabetes therapy Diamyd(R) is to prevent, delay, or stop the autoimmune attack on beta cells in type 1 diabetes and other forms of autoimmune diabetes, thereby prese...
Oasmia Pharmaceutical (publ) is a pharmaceutical company based on the latest concepts of bioorganic chemistry. Our business idea is to improve treatment of common and serious diseases with focus on on...
More Information about "Vitrolife AB (publ)" on BioPortfolio
We have published hundreds of Vitrolife AB (publ) news stories on BioPortfolio along with dozens of Vitrolife AB (publ) Clinical Trials and PubMed Articles about Vitrolife AB (publ) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vitrolife AB (publ) Companies in our database. You can also find out about relevant Vitrolife AB (publ) Drugs and Medications on this site too.
